95 related articles for article (PubMed ID: 11715951)
1. Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinoma.
Figlin RA; Parker SE; Horton HM
Curr Opin Mol Ther; 1999 Apr; 1(2):271-8. PubMed ID: 11715951
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex.
Hoffman DM; Figlin RA
World J Urol; 2000 Apr; 18(2):152-6. PubMed ID: 10854152
[TBL] [Abstract][Full Text] [Related]
3. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo.
Parker SE; Khatibi S; Margalith M; Anderson D; Yankauckas M; Gromkowski SH; Latimer T; Lew D; Marquet M; Manthorpe M; Hobart P; Hersh E; Stopeck AT; Norman J
Cancer Gene Ther; 1996; 3(3):175-85. PubMed ID: 8725882
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J
Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589
[TBL] [Abstract][Full Text] [Related]
5. Leuvectin Vical Inc.
Kaushik A
Curr Opin Investig Drugs; 2001 Jul; 2(7):976-81. PubMed ID: 11757801
[TBL] [Abstract][Full Text] [Related]
6. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex.
Daniels GA; Galanis E
Curr Opin Mol Ther; 2001 Feb; 3(1):70-6. PubMed ID: 11249734
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
Saffran DC; Horton HM; Yankauckas MA; Anderson D; Barnhart KM; Abai AM; Hobart P; Manthorpe M; Norman JA; Parker SE
Cancer Gene Ther; 1998; 5(5):321-30. PubMed ID: 9824052
[TBL] [Abstract][Full Text] [Related]
9. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
Horton HM; Dorigo O; Hernandez P; Anderson D; Berek JS; Parker SE
J Immunol; 1999 Dec; 163(12):6378-85. PubMed ID: 10586027
[TBL] [Abstract][Full Text] [Related]
10. Studies of direct intratumoral gene transfer using cationic lipid-complexed plasmid DNA.
Clark PR; Stopeck AT; Ferrari M; Parker SE; Hersh EM
Cancer Gene Ther; 2000 Jun; 7(6):853-60. PubMed ID: 10880015
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
Galanis E; Hersh EM; Stopeck AT; Gonzalez R; Burch P; Spier C; Akporiaye ET; Rinehart JJ; Edmonson J; Sobol RE; Forscher C; Sondak VK; Lewis BD; Unger EC; O'Driscoll M; Selk L; Rubin J
J Clin Oncol; 1999 Oct; 17(10):3313-23. PubMed ID: 10506635
[TBL] [Abstract][Full Text] [Related]
12. Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft.
Clark PR; Stopeck AT; Parker SE; Hersh EM
Cell Immunol; 2000 Sep; 204(2):96-104. PubMed ID: 11069717
[TBL] [Abstract][Full Text] [Related]
13. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells.
Nishitani MA; Sakai T; Ishii K; Zhang M; Nakano Y; Nitta Y; Miyazaki J; Kanayama HO; Kagawa S; Himeno K
Cancer Gene Ther; 2002 Feb; 9(2):156-63. PubMed ID: 11857033
[TBL] [Abstract][Full Text] [Related]
14. Fusogenic activity of vesicular stomatitis virus glycoprotein plasmid in tumors as an enhancer of IL-12 gene therapy.
Eslahi NK; Muller S; Nguyen L; Wilson E; Thull N; Rolland A; Pericle F
Cancer Gene Ther; 2001 Jan; 8(1):55-62. PubMed ID: 11219494
[TBL] [Abstract][Full Text] [Related]
15. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.
Horiguchi Y; Larchian WA; Kaplinsky R; Fair WR; Heston WD
Gene Ther; 2000 May; 7(10):844-51. PubMed ID: 10845722
[TBL] [Abstract][Full Text] [Related]
16. Direct transfer of IL-12 gene into growing Renca tumors.
Budryk M; Wilczyńska U; Szary J; Szala S
Acta Biochim Pol; 2000; 47(2):385-91. PubMed ID: 11051203
[TBL] [Abstract][Full Text] [Related]
17. Antitumoral effect of a nonviral interleukin-2 gene therapy is enhanced by combination with 5-fluorouracil.
Bishop JS; Thull NM; Matar M; Quezada A; Munger WE; Batten TL; Muller S; Pericle F
Cancer Gene Ther; 2000 Aug; 7(8):1165-71. PubMed ID: 10975677
[TBL] [Abstract][Full Text] [Related]
18. Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma.
Yockman JW; Kim WJ; Chang CW; Kim SW
Gene Ther; 2007 Oct; 14(19):1399-405. PubMed ID: 17653245
[TBL] [Abstract][Full Text] [Related]
19. Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer.
Philip R; Clary B; Brunette E; Kilinski L; Murugesh D; Sorich M; Yau J; Lebkowski J; Lyerly HK; Philip M
Clin Cancer Res; 1996 Jan; 2(1):59-68. PubMed ID: 9816091
[TBL] [Abstract][Full Text] [Related]
20. Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes.
Stopeck AT; Hersh EM; Brailey JL; Clark PR; Norman J; Parker SE
Cancer Gene Ther; 1998; 5(2):119-26. PubMed ID: 9570303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
